{"id":4962,"date":"2023-09-27T16:04:00","date_gmt":"2023-09-27T16:04:00","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=publication&#038;p=4962"},"modified":"2025-09-30T23:56:51","modified_gmt":"2025-09-30T23:56:51","slug":"sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis","status":"publish","type":"publication","link":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/","title":{"rendered":"Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis"},"content":{"rendered":"\n\n\n\n<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Sparsentan Versus Irbesartan in Focal Segmental Glomerulosclerosis<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"margin-top:calc(-150px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\t\t\t\t<div class=\"info-block-type\"><i class=\"icon2-journal\"><\/i> Journal article<\/div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\"><\/i> Published on November 3, 2023\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">FSGS<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\tContributors:<br \/><span>Rheault MN, Alpers CE, Barratt J et al.<\/span>\n\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-box\">\n\t\t\t\t\t\t\tName of Journal:<br \/><span>New England Journal of Medicine<\/span><br \/><br \/><br \/>\n\t\t\t\n\t\t\t\t\t\t\t<a href=\"#\" data-url=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2308550\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"btn btn-outline leaving-modal-toggle btn-leaving\" aria-label=\"View Publication\">View Publication<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"info-block-box info-block-doi\">\n\t\t\t\tDOI:<br \/><span>10.1056\/NEJMoa2308550<\/span>\n\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-share\">Share:\n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fpublications%2Fsparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis%2F&#038;text=Sparsentan+versus+Irbesartan+in+Focal+Segmental+Glomerulosclerosis\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fpublications%2Fsparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis%2F&#038;title=Sparsentan+versus+Irbesartan+in+Focal+Segmental+Glomerulosclerosis\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fpublications%2Fsparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Sparsentan%20versus%20Irbesartan%20in%20Focal%20Segmental%20Glomerulosclerosis&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fpublications%2Fsparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<br \/><br \/><br \/>\n\t\t\t\t\t<div>\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"modal modal-request-copy\" style=\"display: none;\" id=\"modal-request-copy\">\n\t<div class=\"modal__backdrop\">\n\t\t<div class=\"modal__card\">\n\t\t\t<button class=\"modal__close btn-close\" aria-label=\"Close modal\">&times;<\/button>\n\t\t\t<h4 class=\"has-heading-3-font-size\">Request a copy<\/h4>\n\t\t\t\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f2317-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"2317\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/travere-redesign\/wp-json\/wp\/v2\/publication\/4962#wpcf7-f2317-o1\" method=\"post\" class=\"wpcf7-form init wpcf7-acceptance-as-validation\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"2317\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.1\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f2317-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<div class=\"cf7-fields-wrapper\">\n  <div class=\"form-two-cols\">\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-first-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-first-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name*\" value=\"\" type=\"text\" name=\"request-first-name\" \/><\/span>\n    <\/div>\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-last-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-last-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"request-last-name\" \/><\/span>\n    <\/div>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-your-email\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email\" id=\"request-your-email\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email*\" value=\"\" type=\"email\" name=\"request-your-email\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-title\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Title*\" value=\"\" type=\"text\" name=\"request-title\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-agree\"><span class=\"wpcf7-form-control wpcf7-acceptance\"><span class=\"wpcf7-list-item\"><label><input type=\"checkbox\" name=\"request-agree\" value=\"1\" class=\"required\" id=\"request-agree\" aria-invalid=\"false\" \/><span class=\"wpcf7-list-item-label\">All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\">Travere privacy policies<\/a>.<\/span><\/label><\/span><\/span><\/span>\n  <\/div>\n  <div class=\"form-group text-right\">\n    <input class=\"wpcf7-form-control wpcf7-submit has-spinner btn\" id=\"request-submit\" type=\"submit\" value=\"Yes, continue\" \/>\n  <\/div>\n<\/div><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div> <\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-summary\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span class=\"fw-600\">Summary<\/span><\/mark><br><\/h2>\n\n\n\n<h3 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-the-duplex-study-found-a-greater-reduction-in-proteinuria-but-no-significant-difference-in-estimated-glomerular-filtration-rate-egfr-with-sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis-fsgs-1\"><span class=\"fw-600\">The DUPLEX study found a greater reduction in proteinuria but no significant difference in estimated glomerular filtration rate (eGFR) with sparsentan versus irbesartan in focal segmental glomerulosclerosis (FSGS)<sup>1<\/sup><\/span><\/h3>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-background\"><br><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Background<\/mark><\/span><\/h4>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Focal segmental glomerulosclerosis (FSGS) is a leading cause of <span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/kidney-failure-fsgs-usrds-cohort-study\/\" target=\"_blank\" rel=\"noreferrer noopener\">kidney failure<\/a><\/span> worldwide with no approved treatment options available.<sup>2,3<\/sup> Animal models demonstrate angiotensin II (Ang II) and endothelin-1(ET-1) as key mediators of glomerular injury leading to proteinuria.<sup>4<\/sup> Clinical studies have also demonstrated that renin-angiotensin system inhibitors (RASis) and endothelin-1 receptor antagonists (ET<sub>A<\/sub>R), alone or in combination, can reduce proteinuria in human kidney diseases.<sup>5,6<\/sup><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Sparsentan is a first-in-class <span class=\"text-decoration-underline\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\" target=\"_blank\" rel=\"noreferrer noopener\">dual endothelin-angiotensin receptor antagonist<\/a>.<\/span><sup>7<\/sup> The <span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/duet-phase-2-sparsentan-fsgs-efficacy-safety\" target=\"_blank\" rel=\"noreferrer noopener\">Phase 2 DUET study<\/a><\/span> assessed sparsentan versus irbesartan in FSGS and demonstrated a greater proteinuria reduction at 8&nbsp;weeks compared with irbesartan.<sup>7<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-aim\"><br><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Aim<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The DUPLEX study aimed to evaluate the long-term efficacy and safety of sparsentan compared to irbesartan in patients with FSGS.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-approach\"><br><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Approach<\/span><\/mark><\/h5>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>DUPLEX was a <span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/phase-3-sparsentan-irbesartan-fsgs-duplex-study-design\/\" target=\"_blank\" rel=\"noreferrer noopener\">Phase 3, multicenter, double-blind, randomized trial<\/a><\/span> that assessed sparsentan versus irbesartan in FSGS without known secondary causes.<sup>1<\/sup> Eligibility criteria included<sup>1<\/sup>:<\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>Biopsy-confirmed FSGS<\/li>\n\n\n\n<li>Urine protein-creatinine ratio (UPCR) of \u22651.5<\/li>\n\n\n\n<li>Estimated glomerular filtration rate (eGFR) \u226530 mL\/min\/1.73 m<sup>2<\/sup><\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Patients were randomized to sparsentan (n=184; target dose 800 mg\/day) or irbesartan (n=187; target dose 300 mg\/day) for up to 108 weeks.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The primary efficacy endpoint was eGFR slope (rate of change per year) at time of final analysis.<sup>1<\/sup> The secondary endpoint was change in eGFR from baseline to 4 weeks after end of treatment (Week 112).<sup>1<\/sup> Safety was also evaluated.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-findings\"><br><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Findings<\/span><\/mark><\/h5>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><span class=\"fw-600\">Baseline characteristics were similar between treatment groups<sup>1<\/sup><\/span><\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li><span class=\"fw-600\">Mean age (years):<\/span> Sparsentan: 41.7; Irbesartan: 41.5<\/li>\n\n\n\n<li><span class=\"fw-600\">eGFR (mL\/min per 1.73m<sup>2<\/sup>):<\/span> Sparsentan: 63.3; Irbesartan: 64.1<\/li>\n\n\n\n<li><span class=\"fw-600\">Median UPCR (g\/g):<\/span> Sparsentan: 3.1; Irbesartan: 3.0<\/li>\n\n\n\n<li><span class=\"fw-600\">Previous use of RASi:<\/span> Sparsentan: 82.6%; Irbesartan: 76.5%<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><span class=\"fw-600\">There was no significant between-group difference in the eGFR slope after 108 weeks<sup>1<\/sup><\/span><\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>A greater decrease in eGFR over the first 6 weeks was seen with sparsentan versus irbesartan (-4.1 vs -0.8 mL\/min per 1.73 m<sup>2<\/sup>).<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The between-group difference in the slope from Week 6 to Week 108 (i.e. chronic slope) was 0.9 mL\/min\/1.73 m<sup>2<\/sup> per year.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>After 108 weeks, the difference in eGFR total slope was 0.3&nbsp;mL\/min\/1.73&nbsp;m<sup>2 <\/sup>per year (<em>P<\/em>=0.75)<sup>1<\/sup>:<\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li><span class=\"fw-600\">Sparsentan:<\/span> -5.4 mL\/min\/1.73 m<sup>2<\/sup> per year<\/li>\n\n\n\n<li><span class=\"fw-600\">Irbesartan:<\/span> -5.7 mL\/min\/1.73 m<sup>2<\/sup> per year<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><span class=\"fw-600\">Partial remission of proteinuria was higher in the sparsentan group<sup>1<\/sup><\/span><\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In a prespecified interim analysis, the proportion of patients with partial remission of proteinuria at 36 weeks was 42.0% and 26.0% in the sparsentan and irbesartan groups, respectively (<em>P<\/em>=0.009).<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br>Learn more about <span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/duplex-proteinuria-remission-fsgs\/\" target=\"_blank\" rel=\"noreferrer noopener\">achieving proteinuria remission and the effect on progression to kidney failure<\/a><\/span> in a DUPLEX <em>post hoc <\/em>analysis<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><span class=\"fw-600\">Reduction of UPCR was greater in the sparsentan group<sup>1<\/sup><\/span><\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>A greater reduction of UPCR with sparsentan versus irbesartan was seen at 6 weeks and sustained over 108 weeks.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Mean change in UPCR at 108 weeks.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li><span class=\"fw-600\">Sparsentan:<\/span> 50%<\/li>\n\n\n\n<li><span class=\"fw-600\">Irbesartan:<\/span> 32%<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Read more about the <span style=\"text-decoration: underline;\"><a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/era-congress-2025\/#duplex-low-proteinuria\" target=\"_blank\" rel=\"noreferrer noopener\">probability of achieving various proteinuria thresholds<\/a><\/span> in a DUPLEX <em>post hoc <\/em>analysis<\/p>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><span class=\"fw-600\">Sparsentan and irbesartan had similar safety profiles<sup>1<\/sup><\/span><\/p>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Similar rates of adverse events (AEs) were seen in both groups.<sup>1<\/sup> The most common AE was coronavirus disease 2019 (COVID-19), followed by peripheral edema.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-key-takeaway\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\"><br>Key takeaway<\/span><\/mark><\/h5>\n\n\n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The DUPLEX study assessed the efficacy and safety of sparsentan versus irbesartan in FSGS.<sup>1<\/sup> Despite a greater reduction in proteinuria with sparsentan, no significant difference in eGFR slope was observed.<sup>1<\/sup><br><br><br><br><br><\/p>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong> to receive scientific updates<br \/>\nfor healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/publication\/4962#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"publication-related\">\n\t\t<p class=\"has-heading-4-font-size\">Related Content<\/p>\n\t\t<div class=\"publication-related-swiper-container\" style=\"display: none;\">\n\t\t\t<div class=\"swiper publicationSwiper\">\n\t\t\t\t<div class=\"swiper-wrapper\">\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<div class=\"swiper-slide\">\n\t\t\t\t\t\t\t\t<article class=\"m-card  \" aria-label=\"Publication card: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\">\n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-phase-3-duplex-study-fsgs-baseline-characteristics\/\"  aria-label=\"View publication: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\">\n\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1920\" height=\"767\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header.png\" class=\"a-img\" alt=\"Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-300x120.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-1024x409.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-768x307.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-1536x614.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-290x116.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-publication\"><\/i> Publication\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tFocal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\t\t\t\t<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t<em>Kidney International Reports<\/em> \n\t\t\t\t\t &#8211; \t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-phase-3-duplex-study-fsgs-baseline-characteristics\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Read more: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\">\n\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<div class=\"swiper-slide\">\n\t\t\t\t\t\t\t\t<article class=\"m-card  m-card--no-image\" aria-label=\"Publication card: Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\">\n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"#\" class=\"btn-leaving leaving-modal-toggle\" data-url=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/23995270.2025.2461966\" aria-label=\"View publication: Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\">\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-publication\"><\/i> Publication\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tSparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\t\t\t\t<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2025\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"#\" class=\"a-btn a-btn--secondary--blue btn-leaving leaving-modal-toggle\" data-url=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/23995270.2025.2461966\" aria-label=\"Read more: Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\">\n\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t<div class=\"swiper-slide\">\n\t\t\t\t\t\t\t\t<article class=\"m-card  \" aria-label=\"Publication card: Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\">\n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/proteinuria-remission-fsgs-sparsentan-duet-trial\/\"  aria-label=\"View publication: Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\">\n\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1920\" height=\"767\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header.png\" class=\"a-img\" alt=\"Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-300x120.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-1024x409.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-768x307.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-1536x614.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-290x116.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-publication\"><\/i> Publication\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tImplications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\t\t\t\t<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t<em>Kidney International Reports<\/em> \n\t\t\t\t\t &#8211; \t\t\t\t\t2023\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/proteinuria-remission-fsgs-sparsentan-duet-trial\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Read more: Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\">\n\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"swiper-progressbar\"><\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"publication-related-grid search-items__grid search__container\" id=\"search__container\" style=\"display: flex;\">\n\t\t\t\t<article class=\"m-card  \" aria-label=\"Publication card: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\">\n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-phase-3-duplex-study-fsgs-baseline-characteristics\/\"  aria-label=\"View publication: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\">\n\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1920\" height=\"767\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header.png\" class=\"a-img\" alt=\"Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-300x120.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-1024x409.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-768x307.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-1536x614.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/Group-of-people-header-290x116.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-publication\"><\/i> Publication\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tFocal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\t\t\t\t<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t<em>Kidney International Reports<\/em> \n\t\t\t\t\t &#8211; \t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-phase-3-duplex-study-fsgs-baseline-characteristics\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Read more: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study\">\n\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t<article class=\"m-card  m-card--no-image\" aria-label=\"Publication card: Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\">\n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"#\" class=\"btn-leaving leaving-modal-toggle\" data-url=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/23995270.2025.2461966\" aria-label=\"View publication: Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\">\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-publication\"><\/i> Publication\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tSparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\t\t\t\t<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2025\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"#\" class=\"a-btn a-btn--secondary--blue btn-leaving leaving-modal-toggle\" data-url=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/23995270.2025.2461966\" aria-label=\"Read more: Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward\u00a0in Light of the Parasol Initiative\">\n\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t<article class=\"m-card  \" aria-label=\"Publication card: Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\">\n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/proteinuria-remission-fsgs-sparsentan-duet-trial\/\"  aria-label=\"View publication: Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\">\n\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1920\" height=\"767\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header.png\" class=\"a-img\" alt=\"Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-300x120.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-1024x409.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-768x307.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-1536x614.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2023\/10\/pathology-of-igan_header-290x116.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-publication\"><\/i> Publication\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tImplications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\t\t\t\t<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t<em>Kidney International Reports<\/em> \n\t\t\t\t\t &#8211; \t\t\t\t\t2023\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/proteinuria-remission-fsgs-sparsentan-duet-trial\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Read more: Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial\">\n\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t\t<\/div>\n\t\t<div class=\"publication-related-btn\">\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/\" class=\"a-btn a-btn--primary\" aria-label=\"See more\">See more<\/a>\n\t\t<\/div>\n\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-footnotes\" style=\"margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Footnotes<\/mark><\/span><\/h5>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\">Sparsentan is not FDA-approved for the treatment of FSGS.<\/p>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\">AE, adverse event; Ang II, angiotensin II; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; ET-1, endothelin-1; ET<sub>A<\/sub>R, endothelin type A receptor; FDA, Food and Drug Administration; FSGS, focal segmental glomerulosclerosis; RASi, renin-angiotensin system inhibitor; UPCR, urine protein-creatinine ratio.<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Rheault MN et al. <em>N Engl J Med.<\/em> 2023;389(26):2436-2445.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rosenberg AZ, Kopp JB. <em>Clin J Am Soc Nephrol.<\/em> 2017;12(3):502-517.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Gipson DS et al. <em>JAMA Netw Open.<\/em> 2022;5(8):e2228701.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Komers R, Plotkin H. <em>Am J Physiol Regul Integr Comp Physiol.<\/em> 2016;310(10):R877-R884.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Du YH et al. <em>Ann Palliat Med.<\/em> 2022;11(3):1093-1101.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Campbell KN et al. <em>Kidney Med.<\/em> 2022;4(5):100457.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Trachtman H et al. <em>J Am Soc Nephrol.<\/em> 2018;29(11):2745-2754.<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-DS-24-0035 | June 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":4773,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":"","journal_link":"https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2308550","pdf_file_link":""},"product":[78],"therapeutic_area":[97],"disease_area":[186],"study_registry":[187],"study_type":[176],"resource_type":[177,180],"class_list":["post-4962","publication","type-publication","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-fsgs","study_registry-duplex","study_type-clinical","resource_type-publication","resource_type-summary"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>DUPLEX: Sparsentan Versus Irbesartan in FSGS | Travere Medical Affairs<\/title>\n<meta name=\"description\" content=\"Learn about proteinuria and kidney function in DUPLEX, a Phase 3, randomized clinical trial of sparsentan versus irbesartan in FSGS.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis\" \/>\n<meta property=\"og:description\" content=\"Learn about proteinuria and kidney function in DUPLEX, a Phase 3, randomized clinical trial of sparsentan versus irbesartan in FSGS.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-30T23:56:51+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/\",\"name\":\"DUPLEX: Sparsentan Versus Irbesartan in FSGS | Travere Medical Affairs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/sparsentan-clinical-trial_header.png\",\"datePublished\":\"2023-09-27T16:04:00+00:00\",\"dateModified\":\"2025-09-30T23:56:51+00:00\",\"description\":\"Learn about proteinuria and kidney function in DUPLEX, a Phase 3, randomized clinical trial of sparsentan versus irbesartan in FSGS.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/sparsentan-clinical-trial_header.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/sparsentan-clinical-trial_header.png\",\"width\":1920,\"height\":1080,\"caption\":\"Line graph on paper\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/publications\\\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DUPLEX Study Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"DUPLEX: Sparsentan Versus Irbesartan in FSGS | Travere Medical Affairs","description":"Learn about proteinuria and kidney function in DUPLEX, a Phase 3, randomized clinical trial of sparsentan versus irbesartan in FSGS.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis","og_description":"Learn about proteinuria and kidney function in DUPLEX, a Phase 3, randomized clinical trial of sparsentan versus irbesartan in FSGS.","og_url":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-09-30T23:56:51+00:00","twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/","url":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/","name":"DUPLEX: Sparsentan Versus Irbesartan in FSGS | Travere Medical Affairs","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png","datePublished":"2023-09-27T16:04:00+00:00","dateModified":"2025-09-30T23:56:51+00:00","description":"Learn about proteinuria and kidney function in DUPLEX, a Phase 3, randomized clinical trial of sparsentan versus irbesartan in FSGS.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/08\/sparsentan-clinical-trial_header.png","width":1920,"height":1080,"caption":"Line graph on paper"},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/publications\/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"DUPLEX Study Results"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 13:03:10","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"product","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/publication\/4962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/publication"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/4773"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=4962"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=4962"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=4962"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=4962"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=4962"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=4962"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=4962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}